lung-cancer
Lung squamous cell carcinoma (LUSC) is a major lung cancer subtype with limited treatment options and poor outcomes. A key challenge in developing new therapies is the lack of preclinical models that accurately represent the tumor's histological complexity, including keratinizing morphology — a…
lung-cancer
FOXA1 is a 'pioneer' transcription factor that helps establish and maintain the identity of epithelial cells. In early-stage lung adenocarcinoma, FOXA1 keeps cells organized and polarized. This study investigated what happens when FOXA1 function is partially lost.
lung-cancer
Delta-like ligand 3 (DLL3) is a protein selectively expressed on small cell lung cancer (SCLC) cells — and virtually not on normal adult tissue — making it an ideal cancer target. DLL3-targeting therapies are already showing clinical benefit, but understanding what controls DLL3 expression could…
lung-cancer
BRCA1 and BRCA2 are well-known cancer genes in breast and ovarian cancer, but their role in lung cancer is less understood. This study used single-cell sequencing and multi-omics data to characterize how BRCA1/2 mutations reshape the tumor microenvironment in lung adenocarcinoma (LUAD).
lung-cancer
One tissue section can now do the diagnostic work of many in lung cancer — saving scarce biopsy material Lung cancer diagnosis requires multiple rounds of immunohistochemistry (IHC) to classify tumor type, predict drug sensitivity, and guide treatment. Each test uses part of the biopsy, and small samples — common in lung
lung-cancer
Molecular subtype of small cell lung cancer predicts and drives resistance to a newly approved immunotherapy Small cell lung cancer (SCLC) is one of the most aggressive cancers, and new treatment options have been desperately needed. Tarlatamab — a bispecific T-cell engager targeting DLL3 — was recently approved for relapsed SCLC, representing